“Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein”
The overall goal of this protocol is to evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.
Drug - [18F] MNI-946
Subjects will undergo PET imaging using [18F]MNI-946, a PET radioligand for imaging tau.
Drug - [18F]Florbetapir
Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-946.
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers